Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19...
Saved in:
Main Authors: | Maamoun Basheer, Elias Saad, Dorin Shlezinger, Nimer Assy |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c47 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Convalescent Plasma for the Treatment of Severe COVID-19
by: Franchini M, et al.
Published: (2021) -
Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series
by: Theresia Monica Rahardjo, et al.
Published: (2021) -
Convalescent plasma therapy in patients with coronavirus disease-19 – One year after: A brief review
by: Mariela Irabien-Zúñiga, et al.
Published: (2021) -
SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission
by: Hennie Husniah, et al.
Published: (2021) -
Convalescent plasma therapy in an immunocompromised patient with multiple COVID‐19 flares: a case report
by: Frini Karaolidou, et al.
Published: (2021)